Literature DB >> 15536021

Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients.

Naoko Takayanagi1, Tomio Onuma, Shinobu Kato, Kyoko Nishiyama, Takashi Nomiyama, Ryuzo Kawamori.   

Abstract

Small, dense LDL, as well as chylomicron- and VLDL-remnant lipoproteins, are known to be important risk factors for coronary heart disease in patients with type 2 diabetes mellitus. The aim of this study was to clarify the relationship between LDL particle size and postprandial remnant lipoprotein levels in Japanese type 2 diabetic patients. Forty-six patients with type 2 diabetes mellitus were divided into tertiles according to LDL particle size. The peak LDL particle diameter was <26.30 nm in tertile 1, 26.30-26.85 nm in tertile 2, and >26.85 nm in tertile 3. After a test meal, tertile 1 had a significantly greater increment of triglycerides (TG), remnant-like particle (RLP)-TG, and RLP-cholesterol (RLP-C) than tertiles 2 and 3. There was a negative correlation between LDL particle size and the postprandial increases of TG, RLP-TG, and RLP-C. These results indicate that smaller sized LDL particles may be a marker of fasting state for an exaggerated postprandial increase of remnant lipoproteins as well as an increase of TG-rich lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15536021     DOI: 10.1016/j.diabres.2004.04.002

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  2 in total

1.  Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.

Authors:  Yutaka Mori; Genshin Kuriyama; Takaaki Tanaka; Naoko Tajima
Journal:  Endocrine       Date:  2009-10-16       Impact factor: 3.633

2.  Effects of risperidone and olanzapine on remnant-like lipoprotein particle cholesterol (RLP-C) in schizophrenic patients.

Authors:  Takahiko Nagamine
Journal:  Neuropsychiatr Dis Treat       Date:  2008-04       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.